Renal Biomarkers Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Renal Biomarkers Market covers analysis By Marker Type (Functional Biomarker, Up-regulated Protein, Other Biomarker Types); Diagnostic Technique (Enzyme-linked Immunosorbent Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS)); Application (Hospital, Diagnostic Laboratory, Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00004914
  • Category : Biotechnology
  • Status : Upcoming
  • No. of Pages : 150
Buy Now

MARKET OVERVIEW
:
The biomarkers are measurable indicators of presence and severity of any disease that indicates the state of disease for which the therapeutic intervention is planned in accordance. The biomarkers are majorly used to diagnose the presence of any existing as well as developing disease. The renal biomarker checks the appropriate working of kidneys, and developing disease related to kidney by measuring blood and urine level. Biomarkers are needed to prevent the higher rate of kidney disorders and for prediagnosis.

MARKET SCOPE

The "Renal biomarkers market to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of renal biomarkers market with detailed market segmentation by of market type, diagnostic technique, end user. The renal biomarkers market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in renal biomarkers market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  n the basis of market type, the market is segmented into Functional Biomarker, Up-regulated Protein, Other biomarker types.
  •  n the basis of diagnostic technique, the market is segmented into Enzyme-linked Immunosorbent Assay, Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS).
  •  n the basis of end user, the market is segmented into Hospital, Diagnostic Laboratory, Others.

MARKET DYNAMICS
Drivers:

  •  Rising prevalence of various kidney-related diseases
  •  High prevalence of diabetes and high blood pressure.
  •  Rapid technological advancements in the field of genetics

Restraints:

    Issues Related to Regulatory and Reimbursement Systems.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the renal biomarkers market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The renal biomarkers market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting renal biomarkers market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the renal biomarkers market in these regions.

IMPACT OF COVID-19 ON RENAL BIOMARKERS MARKET:

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. The global impacts of the COVID-19 are already starting to be felt, and will significantly affect the renal biomarkers market in 2021.Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

Renal Biomarkers Market Report Analysis

Renal Biomarkers Market
  • CAGR
    CAGR (2023 - 2031)
    XX%
  • Market Size 2023
    US$ XX Million
  • Market Size 2031
    US$ XX Million

Report Coverage

  • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Key future trends
  • Detailed PEST/Porter’s Five Forces and SWOT analysis
  • Industry landscape and competition analysis & recent developments
  • Detailed company profiles
  • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

  • Abbott
  • F. Hoffmann-La Roche AG
  • Beckman Coulter Inc.
  • Siemens Healthcare Diagnostics Inc.
  • Thermo Fisher Scientific Inc.
  • Astute Medical Inc.
  • RenalSense Ltd
  • bioM
  • Randox Laboratories Ltd.

Regional Overview

Regional Overview
  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Market Segment By Marker Type
  • Functional Biomarker
  • Up-regulated Protein
  • Other Biomarker Types
Market Segment By Diagnostic Technique
  • Enzyme-linked Immunosorbent Assay
  • Particle-enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography Mass Spectrometry
Market Segment By Application
  • Hospital
  • Diagnostic Laboratory
MARKET PLAYERS


The report covers key developments in the renal biomarkers market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from renal biomarkers market are anticipated to have lucrative growth opportunities in the future with the rising demand for renal biomarkers market in the global market. Below mentioned is the list of few companies engaged in the renal biomarkers market.

The report also includes the profiles of key players in renal biomarkers market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.

  •  Thermo Fisher Scientific, Inc.
  •  Merck KGaA
  •  PerkinElmer Inc
  •  F. Hoffmann-La Roche
  •  GE Healthcare
  •  New England Biolabs
  •  Promega Corporation
  •  SeraCare Life Sciences, Inc
  •  LI-COR, Inc.
  •  Caprion Biosciences Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Renal Biomarkers Market Report Scope

Report Attribute Details
Market size in 2023 US$ XX Million
Market Size by 2031 US$ XX Million
Global CAGR (2023 - 2031) XX%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Marker Type
  • Functional Biomarker
  • Up-regulated Protein
  • Other Biomarker Types
By Diagnostic Technique
  • Enzyme-linked Immunosorbent Assay
  • Particle-enhanced Turbidimetric Immunoassay
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay
  • Liquid Chromatography Mass Spectrometry
By Application
  • Hospital
  • Diagnostic Laboratory
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott
  • F. Hoffmann-La Roche AG
  • Beckman Coulter Inc.
  • Siemens Healthcare Diagnostics Inc.
  • Thermo Fisher Scientific Inc.
  • Astute Medical Inc.
  • RenalSense Ltd
  • bioM
  • Randox Laboratories Ltd.
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Biotechnology : READ MORE..   

    The List of Companies

    1. Abbott
    2. F. Hoffmann-La Roche AG
    3. Beckman Coulter Inc.
    4. Siemens Healthcare Diagnostics Inc.
    5. Thermo Fisher Scientific Inc.
    6. Astute Medical Inc.
    7. RenalSense Ltd
    8. bioM
    9. Randox Laboratories Ltd.
    10. BIOPORTO A/S
    11. BD
    12. BioMerieux
    13. Pacific Biomarkers